ALNYLAM PHARMACEUTICALS $28.03

up +0.47


21/5/2013 04:21 PM  |  NASDAQ : ALNY  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
12 Mo. Price Change : 178% - ALNY has outperformed the S&P 500 by 152%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. Jefferies Reiterates Buy Rating, $34 PT on Partnership with ...

    Benzinga

  2. A Peek Into The Market Before The Trading Starts

    Benzinga

  3. The Medicines Company, Alnylam Announce Global Alliance

    Benzinga

  4. Alnylam Pharma Offer Results from Phase I Trial, Extension Study ...

    Benzinga

  5. UPDATE: Piper Jaffray Reiterates Overweight Rating, Raises PT on ...

    Benzinga

  6. Alnylam Pharma Announces Exercise of Underwriter's Over-Allotment ...

    Benzinga

  7. Alnylam Pharmaceuticals Prices 8M Share Offering at $20.13/Share

    Benzinga

  8. Alnylam Pharmaceuticals Prices 8M Share Offering at $20.13/Share

    Benzinga

  9. Alnylam Pharma Reports Offering of $125M in Stock

    Benzinga

  10. Alnylam Shares Higher Following New Pre-clinical Data on RNAi ...

    Benzinga

  11. Alnylam, Tekmira Resolve All Litigation; Alnylam to Make $65M ...

    Benzinga

  12. Isis Pharmaceuticals To Receive $1.1 Million From Alnylam

    Benzinga

  13. Alnylam Presents Complete Results from Phase IIb Trial on ...

    Benzinga

  14. Isis Pharma to Receive $1.4M from Alnylan

    Benzinga

  15. Regulus Files Registration Statement for Proposed Initial Public ...

    Benzinga

  16. Myriad Genetics Patents Upheld, But Fight Not Over

    Investors Business Daily

  17. Myriad Genetics Earnings Expected To Stay On Rebound

    Investors Business Daily

  18. Alnylam Pharmaceuticals Soars on Clinical Data Update

    Benzinga

  19. Alnylam Reports Positive ALN-TTR02 Clinical Data, with Robust ...

    Benzinga

  20. Alnylam and Collaborators Publish New Pre-clinical Results with an ...

    Benzinga

  21. Alnylam Announces Top-Line Results of Phase IIb Clinical Trial of ...

    Benzinga

  22. Alnylam Presents Final Results from a Phase I Clinical Trial of ...

    Benzinga

  23. Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN

    at GuruFocus

  24. Alnylam Pharmaceuticals Inc. (ALNY) CEO John Maraganore buys 5,581 ...

    at GuruFocus

  25. Alnylam Pharmaceuticals Inc. (ALNY) President and COO Barry E ...

    at GuruFocus

  26. Rodman & Renshaw Maintains Outperform, $19 PT on Alnylam ...

    at Benzinga

  27. UPDATE: Rodman & Renshaw Raises Target to $19 on Alnylam ...

    at Benzinga

  28. Rodman & Renshaw Raises PT on Alnylam Pharmaceuticals to $19

    at Benzinga

  29. Rodman & Renshaw Maintains Outperform, $12 PT on Alnylam

    at Benzinga

  30. MLV Reiterates Buy, $15 PT on Alnylam Pharmaceuticals

    at Benzinga

  31. Alnylam Files Patent Infringement Suit Against Tekmira

    at Benzinga

  32. Alnylam Pharmaceuticals Inc. (ALNY) CEO John Maraganore buys 1,134 ...

    at GuruFocus

  33. Alnylam Provides Key 2012 Goals; Increases Guidance to End 2011 ...

    at Benzinga

  34. Will Alnylam's Prospective Obesity Drug Change the World Forever?

    at Benzinga

  35. Rodman & Renshaw Reiterates Market Outperform on Alnylam ...

    at Benzinga
People viewing ALNY also viewed: , , , , , ,
Marketplace
Trading Center